Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

Lyell Immunopharma’s recently acquired CAR-T doesn't appear to impress Wall Street. The company said Tuesday that its dual-targeting CD19/CD20 CAR-T called LYL314 induced 22 responses in a cohort of 25 patients ...